The global innovation landscape is rapidly evolving, and across the world, decision makers continue to struggle with the uptake of novel interventions and policies.
The media and social networks echoed yesterday excellent news from the Hospital Clínic of Barcelona, announcing the preliminary results of their newly implemented Artificial Intelligence (AI) based software to treat COVID-19 patients
The immune system is amazingly complex, precise and synchronised to deliver effective responses against most health insults. Likewise, medical challenges need to be faced with a multidisciplinary, coordinated and target-specific approach.
At the intersection of two current topics; the COVID-19 pandemic and the global outcry regarding repeat incidences of racial discrimination and violence in the United States, lies the recent finding that the novel SARS-CoV-2 virus has hit African American and Latino communities harder than others.
In 2016, AQuAS (Catalan Agency for Health Quality and Evaluation), defined indicators used to evaluate the clinical and healthcare quality as a measurement instrument used to evaluate or measure specific aspects of the quality of care.
The R&D response to the SARS-CoV-2 outbreak has been massive, promoted by unprecedented funding to support innovative solutions to fight the COVID-19 pandemic.
Clinical research is essential in contemporary medicine. It is a source of knowledge to improve healthcare, as it which is based on evidence. It helps to evaluate new drugs and , therapies. It is a a necessary step to test new assets but also to develop and gather advice from the best key opinion leaders.
Across all industries 9 out of 10 start-ups will fail. This staggering statistic doesn’t exactly inspire confidence. In healthcare the failure-rate may not be as detrimental but remains cause for concern. Which begs the question: why do so many start-ups fail?